首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献，搜索用时 250 毫秒
1.
为了解广西南宁地区犬细小病毒（CPV）的流行现状与病毒变异情况,本试验对初步确诊为犬细小病毒病的12份阳性病料提取基因组DNA,以提取的基因组DNA为模板,通过PCR扩增VP2基因序列并测序,将12个阳性毒株样本VP2基因测序结果与GenBank中登录的17株国内外CPV分离株VP2基因进行同源性比对,采用Mega 7.0软件绘制遗传进化树,分析其病毒亚型和遗传进化情况。结果显示,成功扩增得到12个毒株样本的VP2基因片段,大小约1 755 bp,12株阳性样本毒株的VP2基因同源性在99.2%~100.0%之间,其中NN01与NN07、NN02与NN06同源性最高,为100.0%;阳性样本毒株与国内其他分离株VP2基因的同源性为97.6%~100.0%,其中NN08、NN10及NN04与CPV-ZJ1579同源性最高,均为100.0%,属于CPV-2a亚型;阳性样本毒株与国外代表性毒株同源性在98.1%~99.8%之间。遗传进化树分析表明,12个样本毒株中有3株属于CPV-2a亚型,3株属于CPV-2b亚型,6株属于CPV-2c亚型。这是继2018年初广西分离到CPV-2c型CPV后,首次发现南宁地区大规模流行CPV-2c亚型病毒,预示着CPV-2c亚型CPV在国内的流行正在增加。综上所述,广西南宁地区CPV-2a、CPV-2b与CPV-2c亚型并存,但CPV-2c亚型的比重比其他地区大,这也给该地区提供了新的防治信息,在实际CPV防控工作中除了对CPV-2a、CPV-2b等传统流行亚型的关注之外,更应该重视CPV-2c亚型CPV的防控。  相似文献   

2.
为了解广西南宁地区犬细小病毒(CPV)的流行现状与病毒变异情况,本试验对初步确诊为犬细小病毒病的12份阳性病料提取基因组DNA,以提取的基因组DNA为模板,通过PCR扩增VP2基因序列并测序,将12个阳性毒株样本VP2基因测序结果与GenBank中登录的17株国内外CPV分离株VP2基因进行同源性比对,采用Mega 7.0软件绘制遗传进化树,分析其病毒亚型和遗传进化情况。结果显示,成功扩增得到12个毒株样本的VP2基因片段,大小约1 755bp,12株阳性样本毒株的VP2基因同源性在99.2%～100.0%之间,其中NN01与NN07、NN02与NN06同源性最高,为100.0%;阳性样本毒株与国内其他分离株VP2基因的同源性为97.6%～100.0%,其中NN08、NN10及NN04与CPV-ZJ1579同源性最高,均为100.0%,属于CPV-2a亚型;阳性样本毒株与国外代表性毒株同源性在98.1%～99.8%之间。遗传进化树分析表明,12个样本毒株中有3株属于CPV-2a亚型,3株属于CPV-2b亚型,6株属于CPV-2c亚型。这是继2018年初广西分离到CPV-2c型CPV后,首次发现南宁地区大规模流行CPV-2c亚型病毒,预示着CPV-2c亚型CPV在国内的流行正在增加。综上所述,广西南宁地区CPV-2a、CPV-2b与CPV-2c亚型并存,但CPV-2c亚型的比重比其他地区大,这也给该地区提供了新的防治信息,在实际CPV防控工作中除了对CPV-2a、CPV-2b等传统流行亚型的关注之外,更应该重视CPV-2c亚型CPV的防控。  相似文献   

3.
为了解山东省犬细小病毒(CPV)流行毒株的遗传变异情况及其与犬细小病毒病的分子流行病学关系,对2013年分离到的12株山东CPV流行毒株进行了VP2基因克隆测序与同源性分析,绘制系统进化树。结果表明,获得的VP2基因的全长为1 755 bp,编码584个氨基酸残基;各分离毒株之间的核苷酸和氨基酸同源率分别为98.9%~100.0%和98.8%~100.0%,与Gen Bank公布的国内外参考毒株核苷酸和氨基酸同源率在98%以上,分离株VP2基因及其推导的氨基酸的变异主要以点突变为主,关键氨基酸位点未见明显改变。遗传进化分析显示,有8株为New CPV-2a,4株为New CPV-2b,表明目前山东省所流行的CPV主要以New CPV-2a亚型为主。研究结果为山东犬细小病毒病的防控提供了依据。  相似文献   

4.
为了调查广西地区犬细小病毒(CPV)的优势毒株及其遗传变异情况,试验利用PCR方法对采自广西地区的423份犬血清样本进行CPV检测并扩增其VP2基因,利用MegAlign软件进行同源性比对并分析VP2蛋白主要突变的氨基酸位点,同时利用MEGA 7.0软件采用邻接法构建遗传进化树。结果表明：共获得55份CPV阳性血清样本,阳性率约为13.0%。PCR扩增得到大小约为1 755 bp的VP2基因。55株分离毒株之间的相似性为98.6%～100%;分离毒株与国内外参考毒株的相似性为97.4%～100%,与疫苗株Pfizer/vaccine/06的相似性为98.3%～98.9%。扩增序列的推导氨基酸主要在第5,297,370,426,440位发生变异。在55株分离毒株中,有32株为New CPV-2a亚型毒株,20株为CPV-2c亚型毒株,3株为New CPV-2b亚型毒株。55株分离毒株形成3个主要的流行分支,与国内参考毒株的亲缘关系较近,而与国外参考毒株、猫细小病毒的亲缘关系较远。说明New CPV-2a、CPV-2c、New CPV-2b亚型毒株在广西地区流行广泛,正逐步取代CPV-2a...  相似文献   

5.
犬细小病毒(CPV)可引起犬的严重的出血性肠炎，是重要的致病因子，1978年最初从美国分离到，并迅速传播到世界各地，导致许多犬死亡，这个毒株命名为CPV2型(CPV-2)，以和非致病性的犬细小病毒和犬微小病毒进行区分。CPV-2出现后，又分离到新的抗原变异株CPV2a型(CPV-2a)和CPV2b型(CPV-2b)。1985年，CPV-2a和CPV-2b完全取代了CPV-2。  相似文献   

6.
从北京地区疑似细小病毒感染的犬粪拭子中成功分离鉴定出14株犬细小病毒（CPV）毒株,并对其完整的VP2和NS1基因进行了序列分析。结果表明,鉴定到的14株CPV毒株中,7株为New CPV-2a型,7株为CPV-2c型。此外,NS1的19、33、293、588、624和656位氨基酸以及VP2的13、574位氨基酸为新鉴定的氨基酸突变位点。基于VP2、NS1基因的系统进化分析表明,大部分的New CPV-2a型和CPV-2c型毒株与广西南宁和吉林长春地区的分离毒株亲缘关系密切,说明本次分离毒株与广西或吉林地区分离毒株具有相同的起源。本研究为更好地开展犬细小病毒流行病学调查提供了有益借鉴,也为深入研究犬细小病毒变异和传播的分子机制奠定了基础。  相似文献   

7.
从疑似患细小病毒性肠炎的貉子肠道组织样品中分离到一株貉细小病毒(RDPV-SD1607)。为研究其分子遗传特征,对该分离株VP2基因进行克隆序列分析,结果显示,RDPV-SD1607的VP2序列与RDPV-HB3的相似性最高,为99.49%,属于CPV-2亚型;利用其核苷酸序列建立系统进化树发现,RDPV-SD1607处于犬细小病毒分支,且处于CPV-2亚型和CPV-2a亚型分支之间。结果表明,RDPV-SD1607株与犬细小具有共同的遗传起源,推测其可能正处于CPV-2亚型向CPV-2a亚型进化的中间状态,或是CPV适应貉而形成的新毒株。  相似文献   

8.
为研究贵阳地区犬细小病毒（canine parvovirus,CPV）的流行基因型及其遗传进化情况,本试验对从贵阳市分离的10株CPV的VP2基因进行PCR扩增和克隆并进行序列分析。结果显示,分离的病毒能使F81猫肾细胞产生明显的细胞病变（CPE）,分离的10株病毒中,7株为CPV-2a亚型,3株为CPV-2c亚型,命名为GY-1~GY-10。10株CPV分离株与疫苗株VP2基因的同源性98.4%~99.4%,与其他国内外参考株的同源性为97.7%~99.9%。本试验首次报道贵阳市CPV的流行基因型为CPV-2a亚型并伴随CPV-2c亚型存在,对监测CPV遗传变异趋势及疫苗的研制具有重要意义。  相似文献   

9.
为了探明青岛地区免疫过犬细小病毒(CPV)疫苗的犬因犬细小病毒感染死亡的原因，本研究采用全基因序列测定、系统进化树构建、基因分型和氨基酸分析的方法，对从临床发病犬中分离的3株CPV进行分析。结果显示，本实验室于2012年和2015年分离到的2株病毒(CPV-QD12和CPV-QD15)为new CPV-2a型，本研究分离到的1株病毒(CPV-QD20)为CPV-2c型；3株CPV在VP2的第5、267、297、324、370、426、440位氨基酸，NS1的第60、544、545、572、624、630位氨基酸发生了非同义替代。目前广泛使用的进口CPV弱毒活疫苗的基因型为原始的CPV-2型，与CPV流行毒株的基因型存在差异，这可能是造成CPV临床免疫失败的重要原因。因此，为了提升CPV疫苗的保护效率，建议使用CPV流行毒株研发CPV疫苗。  相似文献   

10.
本试验成功分离了1株犬细小病毒,采用PCR、理化特性检验、HA及HI等方法对其进行了鉴定,并对其编码区全基因序列进行了分析。取临床患出血性肠炎幼犬粪便经无菌处理后同步接种F81猫肾细胞分离病毒,盲传至第4代开始出现典型的细胞病变。该病毒可凝集猪的红细胞,血凝效价为28,可被犬细小病毒单克隆抗体特异性中和而产生血凝抑制现象;病毒效价为105.5TCID50/m L;毒株对氯仿和胰酶不敏感,且耐酸耐热。经病毒理化特性试验及犬细小病毒单克隆抗体的血凝抑制鉴定其为犬细小病毒,通过PCR检测及编码区全基因的扩增、测序和序列比较,证实所分离毒株为CPV-2a亚型,并将其命名为CPV-QD12株,与2013年分离自中国江苏省的CPV-2a型犬细小毒株CPV-JS2及2011年分离自中国广西的CPV-2a型毒株CPV-JQ686671.1的编码区核苷酸相似性为99.6%,具有较近的亲缘关系。该研究可为诊断和防控犬细小病毒病提供参考。  相似文献   

11.
Canine parvovirus (CPV) was first isolated in 1978 in the USA. Analysis of CPV isolates by monoclonal antibodies and restriction enzymes have shown that after the first emergence of CPV (CPV-2) it evolved to give rise to new antigenic types, which were designated CPV type 2a and type 2b. These new types have replaced the original CPV type 2, although the proportions of each of the new antigenic types vary in different countries. In Brazil, CPV-like infections were first observed in 1979, however, there has been no information concerning the antigenic types of CPV prevailing in South America. In this study, we designed a PCR assay to type canine parvovirus strains in fecal samples collected from symptomatic dogs during 1980 through 1986 and 1990 through 1995. Our data showed that the CPV epizootic in Brazil followed the same pattern observed in the USA of emergence of CPV-2 followed by replacement by the variants CPV-2a and 2b. The predominant strain found during 1980 was CPV-2a, which was substantially replaced by CPV-2b from 1990 to 1995.  相似文献   

12.
Occurrence of canine parvovirus type 2c in the United States.   总被引：3，自引：0，他引：3  
Canine parvovirus (CPV) type 2 (CPV-2) emerged around 1978 as a major pathogen of dogs worldwide. In the mid-1980s, the original CPV-2 had evolved and was completely replaced by 2 variants, CPV-2a and CPV-2b. In 2000, a new variant of CPV (named CPV-2c) was detected in Italy and now cocirculates with types 2a and 2b in that country. The CPV-2c has also been reported from single outbreaks in Vietnam and Spain. This study was conducted to determine if CPV-2c occurs in the United States. Thirty-three fecal samples were collected from dogs in 16 states between April 2006 and April 2007 and were tested for CPV using real-time polymerase chain reaction (PCR). Positive samples were further tested using conventional PCR and minor-groove binding TaqMan PCR assays to determine the viral type and to differentiate vaccine strains from field strains. Twenty-seven samples were positive for CPV, 7 of which were CPV-2c from 5 states: Arizona, California, Georgia, Oklahoma, and Texas. Of the 7 isolates, 4 differed from European CPV-2c isolates by 2 additional single-nucleotide mutations at positions 4076 and 4104, the latter of which produces a ThrAla change at residue 440 located near a major antigenic site. The coast-to-coast geographic distribution of the states in which CPV-2c was detected strongly suggests that this new CPV variant is probably widespread in the United States. The continuous evolution of CPV requires that monoclonal antibody-based and nucleic acid-based diagnostic assays should be periodically checked for sensitivity on prevalent CPV strains.  相似文献   

13.
Fifty-five canine parvovirus type 2 (CPV) samples, 12 fecal specimens and 43 cell culture isolates, were examined for their genetic characteristics of VP2 gene. They were collected from the diseased dogs at various districts of Japan during 27 years from 1980 to 2006. A fragment of VP2 gene was analyzed by restriction fragment length polymorphism assay and DNA sequencing. The original antigenic type 2 of CPV (CPV-2) was no longer found in the samples since 1984, and two antigenic variants CPV-2a and CPV-2b replaced CPV-2 as predominant types for about 5 years from 1982. A new genetic variant of prototype CPV-2a with non-synonymous substitution at the VP2 amino acid residue 297 from Ser to Ala was first detected in 1987. New CPV-2b with the same amino acid substitution at position 297 as new CPV-2a was also detected from the samples collected in 1997. Since then new CPV-2b has been the predominant CPV over the field of Japan. Several additional amino acid substitutions were detected in the VP2 gene of some recent CPV strains. Neither CPV-2c(a), CPV-2c(b), nor "Glu-426" of the antigenic variants previously found outside the country was detected in any samples tested. Reactivity of new CPV-2a and 2b variants against antibodies produced by the current vaccine products was determined by a cross hemagglutination-inhibition test. The recent field CPV isolates reacted more efficiently to the antibodies produced in dogs vaccinated with the new CPV-2b vaccine strain than the conventional CPV-2 vaccine strain.  相似文献   

14.
A case of canine parvovirus type 2c (CPV-2c) infection in a 3-month-old feral kitten with a cerebral abscess and neurological disease is reported. The cat displayed ataxia and convulsions together with signs of gastroenteritis and profound alteration of the total and differential white blood cell counts. A parvovirus strain was detected by a TaqMan assay in the blood and faeces of the affected kitten, which was characterised as CPV by means of molecular assays but did not react with any of the CPV type-specific probes. By sequence and phylogenetic analyses of the VP2-protein gene, the CPV-2c strain displayed a non-coding mutation in the probe-binding region. Although the role of CPV-2c in this particular case is unclear, it is possible that it predisposed the kitten to the clinical signs seen. Continuous surveillance is needed to monitor future spreading of this CPV-2c mutant, and any associated clinical signs, in the dog and cat population.  相似文献   

15.
Canine parvovirus type 2 (CPV-2) emerged in late 1970s causing severe epizootics in kennels and dog shelters worldwide. Soon after its emergence, CPV-2 underwent genetic evolution giving rise consecutively to two antigenic variants, CPV-2a and CPV-2b that replaced progressively the original type. In 2000, a new antigenic variant, CPV-2c, was detected in Italy and rapidly spread to several countries. In comparison to the original type CPV-2, the antigenic variants display increased pathogenicity in dogs and extended host range, being able to infect and cause disease in cats. Epidemiological survey indicate that the newest type CPV-2c is becoming prevalent in different geographic regions and is often associated to severe disease in adult dogs and also in dogs that have completed the vaccination protocols. However, the primary cause of failure of CPV vaccination is interference by maternally derived immunity. Diagnosis of CPV infection by traditional methods has been shown to be poorly sensitive, especially in the late stages of infections. New diagnostic approaches based on molecular methods have been developed for sensitive detection of CPV in clinical samples and rapid characterisation of the viral type. Continuous surveillance will help assess whether there is a real need to update currently available vaccines and diagnostic tests.  相似文献   

16.
Canine parvovirus 2 (CPV-2) causes a highly contagious and often fatal disease in dogs. Since its sudden emergence in the early 1970s, CPV-2 has been evolving through the generation of novel genetic and antigenic variants (CPV-2a/b/c) that are unevenly distributed throughout the world. In the present study we have examined 36 clinical cases of dogs suspected of CPV collected during year 2006. A fragment of the VP2 gene of the virus was analyzed using polymerase chain reaction (PCR), restriction endonuclease (RE) and DNA sequence analysis. Out of the 36 samples analyzed, 16 were found positive for CPV-2a/2b by conventional PCR. DNA sequencing was done for 6 PCR positive samples, out of which three were characterized as CPV-2c, indicating that this CPV type 2c is currently circulating in India.  相似文献   

17.
Canine parvovirus type 2a (CPV-2a) and type 2b (CPV-2b) have recently been isolated from cats throughout the world, and CPV-2b strain FP84 has been reported to be virulent in domestic cats. Although live feline panleucopenia virus (FPLV) vaccines protect domestic cats from CPV infection, the efficacy of inactivated FPLV vaccines has not been established. In this study, two domestic cats were vaccinated with a commercial inactivated FPLV vaccine and challenged with CPV-2b strain FP84 isolated from a domestic cat. The cats were protected against CPV-2b strain FP84 infection and their clinical signs were suppressed, although the two unvaccinated cats showed the typical clinical signs of parvovirus infection.  相似文献   

18.
Canine parvovirus 2c infection in central Portugal   总被引：1，自引：0，他引：1  
Canine parvovirus (CPV) has been evolving, generating new genetic and antigenic variants throughout the world. This study was conducted to determine the types of CPV circulating in dogs in Figueira da Foz, Portugal. Thirty fecal samples, collected between 2006 and 2007 from dogs with clinical signs of CPV infection, were tested for CPV by a rapid, in-clinic, enzyme-linked immunosorbent assay (ELISA)/immunomigration test, by conventional real-time polymerase chain reaction (PCR), and by minor-groove binding TaqMan PCR. Of the 29 PCR-positive samples, 15 were identified as CPV-2b and 14 as CPV-2c. No CPV-2a was detected. The sensitivity of the ELISA test was 82.76% compared with the PCR assays. No significant associations were found between CPV type, clinical outcome, breed, vaccination status, or age.  相似文献   

19.
Recent identification of unusual canine parvovirus (CPV) mutants in cats and dogs suggests that CPV type 2 (CPV-2), which emerged suddenly in the late 1970s, is undergoing continual genetic and antigenic variations. A peculiarity of parvoviruses is that single-nucleotide substitutions may determine drastic phenotypic changes. The effects of either natural or artificial mutations on CPV phenotypic properties have been largely investigated, and this sets up CPV as an interesting model to study virus evolution. By monitoring the evolution of CPV-2 in Italy, we observed the onset and quick spread of a Glu-426 mutant, antigenically different from the pre-existing variants that were partially displaced within a few years of the initial identification of the new mutant. The identification of CPV-2 variants raises several questions concerning their impact on the efficacy of the current CPV-2 vaccines, based on the original CPV-2 strain that no longer exists in the field.  相似文献   

20.
A novel peptide nucleic acid (PNA)-based array was developed for use in ante-mortem antigenic typing discrimination in dogs with canine parvovirus (CPV). Cyclic benzothiazole-2-sulfonyl PNA monomers were synthesized that recognized GTA (CPV-2) and TAT (CPV-2a, -2b and -2c) at the nt 913–915 positions, and AAT (CPV-2 and CPV-2a), GAT (CPV-2b), and GAA (CPV-2c) at the nt 1276–1278 positions of the VP2 gene. The detection limits for aa 305 and aa 426 of the VP2 proteins belonging to the four CPV antigenic types were determined optically to be 40–2000 DNA copies, and the optimal cut-off fluorescence signaling value was fixed at 5000. The PNA array described here was developed from 135 field dog fecal specimens and had 89.8% (62/69) sensitivity and 90.4% (66/73) specificity compared with a real-time PCR using the TaqMan assay, a gold standard method. This CPV PNA array could be used together with MGB probe assays as an attractive novel tool for ante-mortem antigenic typing discrimination.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号